Product Information
CEFPROZIL 125 MG/5 ML SUSP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1049 per ML under NDC 68180040103. Its NADAC has been published 659 times since Nov 28, 2013.
FDA first approved this application on Dec 19, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
125 mg/5mL
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180040103
Classification
Generic
Dosage Form
POWDER, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEFPROZILApproval Type
Generic (ANDA)
FDA Application
ANDA065261FDA Approved
12/19/2005
TE Code
AB
On Market Since
12/1/2005
Price Statistics
The NADAC for CEFPROZIL 125 MG/5 ML SUSP has been published 659 times since Nov 28, 2013, and over the history we have for it it has declined 66.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1049 per ML |
|---|---|
| All-time high | $0.3098 (Dec 11, 2013) |
| All-time low | $0.0917 (Jan 18, 2023) |
| 52-week high | $0.1342 |
| 52-week low | $0.0986 |
| Median price | $0.1806 |
| Average price | $0.1976 |
| Largest weekly change | +73.0% (May 18, 2022) |
| Weeks tracked | 659 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CEFPROZIL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CEFPROZIL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFPROZIL 125 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CEFPROZIL 125 MG/5 ML SUSP, manufactured by Lupin Pharmaceuticals Inc., is $0.1049 per ML (NDC 68180040103), effective Sep 30, 2026.
How has the price of CEFPROZIL 125 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CEFPROZIL 125 MG/5 ML SUSP has declined 66.1%. It has been tracked across 659 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CEFPROZIL 125 MG/5 ML SUSP?
Since Nov 28, 2013, the NADAC for CEFPROZIL 125 MG/5 ML SUSP has ranged from a low of $0.0917 (Jan 18, 2023) to a high of $0.3098 (Dec 11, 2013), with a median of $0.1806 per ML.
Are there cheaper alternatives to CEFPROZIL 125 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of CEFPROZIL 125 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CEFPROZIL 125 MG/5 ML SUSP?
CEFPROZIL 125 MG/5 ML SUSP (NDC 68180040103) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.